Dual-Action Hexanohydroxamic Acid Inhibitors for HDAC and HMGR
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments using multi-component drug cocktails face challenges such as complex pharmacokinetics, unpredictable drug interactions, and formulation issues due to differing solubilities of individual drugs, highlighting the need for a single compound that can simultaneously modulate multiple targets like histone deacetylases (HDACs) and 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGR).
Innovation Solution
Development of novel hexanohydroxamic acid derivatives that act as potent inhibitors of both HDACs and HMGRs, offering a dual-action approach for cancer treatment by targeting these enzymes simultaneously.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If multi-component drug cocktails are used to target multiple enzymes, then the therapeutic effectiveness is improved, but the device complexity and pharmacokinetic complexity increase
Solution Approach 1:
The patent combines multiple drug functions into a single dual-action molecule that can simultaneously inhibit both HDAC and HMGR enzymes. This merging approach maintains the therapeutic effectiveness of targeting multiple enzymes while eliminating the pharmacokinetic complexity and drug interaction issues associated with multi-component cocktails.
Solution Approach 2:
The invention creates a universal compound capable of performing multiple functions by simultaneously targeting two different enzyme pathways (HDAC and HMGR). This multi-functional molecule addresses the limitations of single-target therapies while avoiding the complexities of combination therapies.
2Reliability
If multiple drugs are combined to target different enzymes, then the synergistic therapeutic benefit is improved, but the formulation difficulty increases due to different solubilities
Solution Approach 1:
By merging the therapeutic benefits of two drugs with different solubility profiles into a single molecular entity, the patent eliminates formulation difficulties while preserving the synergistic therapeutic effect of dual enzyme inhibition.
3Adaptability or versatility
If multi-component drug cocktails are used, then multiple targets are modulated, but the drug-drug interaction unpredictability increases
Solution Approach 1:
The patent creates a reliable multi-target agent by designing a single molecule with dual functionality. This approach ensures predictable pharmacokinetics and eliminates unpredictable drug-drug interactions while maintaining the ability to modulate multiple enzyme targets simultaneously.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds demonstrate potent inhibition of HDACs and HMGRs, potentially leading to effective treatment of various diseases, including cancer, by promoting histone acetylation and reducing HMGR activity, thus offering a synergistic therapeutic benefit.
Implementation Method 1
certain hexanohydroxamic acid derivatives are potent inhibitors of HDACs and HMGRs
Implementation Method 2
certain hexanohydroxamic acid derivatives are potent inhibitors of HDACs and HMGRs
Data Source
AI summary
Disclosed herein are novel compounds of formula (I), and uses thereof. The compounds of Formula (I) are inhibitors of histone deacetylases (HDACs) and 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase (HMGR). Also provided are methods of using the compounds of Formula (I) for inhibiting the activity of HDACs and HMGR, treating diseases associated with HDACs or HMGR (e.g., cancer, hypercholesterolemia, an acute or chronic inflammatory disease, autoimmune disease, allergic disease, pathogen infection, neurodegenerative disease, or a disease associated with oxidative stress,